<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ULTRAM- tramadol hydrochloride tablet, coated </strong><br>A-S Medication Solutions LLC<br></p></div>
<h1>ULTRAM<span class="Sup">®</span>	C IV <br> (tramadol hydrochloride) Tablets</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">Full Prescribing Information</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">ULTRAM<span class="Sup">®</span> (tramadol hydrochloride) tablets is a centrally acting analgesic. The chemical name for tramadol hydrochloride is (±)<span class="Italics">cis</span>-2-[(dimethylamino)methyl]-1-(3-methoxyphenyl) cyclohexanol hydrochloride. Its structural formula is:</p>
<div class="Figure"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=288ddb7b-29e4-46c7-9d84-38a188231710&amp;name=ultram-01.jpg"></div>
<p>The molecular weight of tramadol hydrochloride is 299.8. Tramadol hydrochloride is a white, bitter, crystalline and odorless powder. It is readily soluble in water and ethanol and has a pKa of 9.41. The n-octanol/water log partition coefficient (logP) is 1.35 at pH 7. ULTRAM<span class="Sup">®</span> tablets contain 50 mg of tramadol hydrochloride and are white in color. Inactive ingredients in the tablet are pregelatinized corn starch, modified starch (corn), hypromellose, lactose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, polysorbate 80, sodium starch glycolate, titanium dioxide and carnauba wax.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43681-6">
<a name="section-3.1"></a><p></p>
<h2>Pharmacodynamics</h2>
<p class="First">ULTRAM<span class="Sup">®</span> contains tramadol, a centrally acting synthetic opioid analgesic. Although its mode of action is not completely understood, from animal tests, at least two complementary mechanisms appear applicable: binding of parent and M1 metabolite to µ-opioid receptors and weak inhibition of re-uptake of norepinephrine and serotonin.</p>
<p>Opioid activity is due to both low affinity binding of the parent compound and higher affinity binding of the O-demethylated metabolite M1 to µ-opioid receptors. In animal models, M1 is up to 6 times more potent than tramadol in producing <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> and 200 times more potent in µ-opioid binding. Tramadol-induced <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> is only partially antagonized by the opiate antagonist naloxone in several animal tests. The relative contribution of both tramadol and M1 to human <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> is dependent upon the plasma concentrations of each compound (see<span class="Bold"><a href="#Pharmacokinetics"> CLINICAL PHARMACOLOGY, Pharmacokinetics</a></span>).</p>
<p>Tramadol has been shown to inhibit reuptake of norepinephrine and serotonin<span class="Italics"> in vitro, </span>as have some other opioid analgesics. These mechanisms may contribute independently to the overall analgesic profile of ULTRAM<span class="Sup">®</span>. <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">Analgesia</span> in humans begins approximately within one hour after administration and reaches a peak in approximately two to three hours.</p>
<p>Apart from <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span>, ULTRAM<span class="Sup">®</span> administration may produce a constellation of symptoms (including <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span> and <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>) similar to that of other opioids. In contrast to morphine, tramadol has not been shown to cause histamine release. At therapeutic doses, ULTRAM<span class="Sup">®</span> has no effect on heart rate, left-ventricular function or <span class="product-label-link" type="condition" conceptid="4208254" conceptname="Cardiac index">cardiac index</span>. <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">Orthostatic hypotension</span> has been observed.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="section-3.2"></a><p></p>
<h2>Pharmacokinetics</h2>
<p class="First">The analgesic activity of ULTRAM<span class="Sup">®</span> is due to both parent drug and the M1 metabolite (see<span class="Bold"><a href="#Pharmacodynamics"> CLINICAL PHARMACOLOGY, Pharmacodynamics</a></span>). Tramadol is administered as a racemate and both the [-] and [+] forms of both tramadol and M1 are detected in the circulation. Linear pharmacokinetics have been observed following multiple doses of 50 and 100 mg to steady-state.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.2.1"></a><p></p>
<h3>Absorption</h3>
<p class="First">The mean absolute bioavailability of a 100 mg oral dose is approximately 75%. The mean peak plasma concentration of racemic tramadol and M1 occurs at two and three hours, respectively, after administration in healthy adults. In general, both enantiomers of tramadol and M1 follow a parallel time course in the body following single and multiple doses although small differences (~ 10%) exist in the absolute amount of each enantiomer present.</p>
<p>Steady-state plasma concentrations of both tramadol and M1 are achieved within two days with four times per day dosing. There is no evidence of self-induction (see<a href="#fig1"> Figure 1 </a>and<a href="#table1"> Table 1 </a>below).</p>
<p><span class="Bold">Figure 1:	Mean Tramadol and M1 Plasma Concentration Profiles after a Single 100 mg Oral Dose and after Twenty-Nine 100 mg Oral Doses of Tramadol HCl given four times per day.</span></p>
<p><a name="fig1"></a><img alt="Figure 1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=288ddb7b-29e4-46c7-9d84-38a188231710&amp;name=ultram-02.jpg"></p>
<a name="table1"></a><table width="85%">
<caption><span>Table 1	Mean (%CV) Pharmacokinetic Parameters for Racemic Tramadol and M1 Metabolite</span></caption>
<col align="left" valign="top" width="22%">
<col align="center" valign="top" width="16%">
<col align="center" valign="top" width="16%">
<col align="center" valign="top" width="16%">
<col align="center" valign="top" width="16%">
<col align="center" valign="top" width="14%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left">Population/ Dosage Regimen<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a>
</th>
<th class="Rrule" align="center">Parent Drug/ Metabolite</th>
<th class="Rrule" align="center">Peak Conc. (ng/mL)</th>
<th class="Rrule" align="center">Time to Peak (hrs)</th>
<th class="Rrule" align="center">Clearance/F<a name="footnote-reference-2" href="#footnote-2" class="Sup">†</a> (mL/min/Kg)</th>
<th class="Rrule" align="center">t<span class="Sub">1/2</span> (hrs)</th>
</tr></thead>
<tfoot><tr><td colspan="6" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>SD = Single dose, MD = Multiple dose, p.o.= Oral administration,<br>i.v.= Intravenous administration, q.i.d. = Four times daily</dd>
<dt><a name="footnote-2" href="#footnote-reference-2">†</a></dt>
<dd>F represents the oral bioavailability of tramadol</dd>
<dt><a name="footnote-3" href="#footnote-reference-3">‡</a></dt>
<dd>Not applicable</dd>
<dt><a name="footnote-4" href="#footnote-reference-4">§</a></dt>
<dd>Not measured</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Lrule Rrule" align="left">Healthy Adults, 100 mg qid, MD p.o.</td>
<td class="Rrule" align="center">Tramadol<br>M1</td>
<td class="Rrule" align="center">592 (30)<br>110 (29)</td>
<td class="Rrule" align="center">2.3 (61)<br>2.4 (46)</td>
<td class="Rrule" align="center">5.90 (25)<br><a name="footnote-reference-3" href="#footnote-3" class="Sup">‡</a>
</td>
<td class="Rrule" align="center">6.7 (15)<br>7.0 (14)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left">Healthy Adults, 100 mg SD p.o.</td>
<td class="Rrule Toprule" align="center">Tramadol<br>M1</td>
<td class="Rrule Toprule" align="center">308 (25)<br>55.0 (36)</td>
<td class="Rrule Toprule" align="center">1.6 (63)<br>3.0 (51)</td>
<td class="Rrule Toprule" align="center">8.50 (31)<br><a href="#footnote-3" class="Sup">‡</a>
</td>
<td class="Rrule Toprule" align="center">5.6 (20)<br>6.7 (16)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left">Geriatric, (&gt;75 yrs) 50 mg SD p.o.</td>
<td class="Rrule Toprule" align="center">Tramadol<br>M1</td>
<td class="Rrule Toprule" align="center">208 (31)<br><a name="footnote-reference-4" href="#footnote-4" class="Sup">§</a>
</td>
<td class="Rrule Toprule" align="center">2.1 (19)<br><a href="#footnote-4" class="Sup">§</a>
</td>
<td class="Rrule Toprule" align="center">6.89 (25)<br><a href="#footnote-3" class="Sup">‡</a>
</td>
<td class="Rrule Toprule" align="center">7.0 (23)<br><a href="#footnote-4" class="Sup">§</a>
</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left">Hepatic Impaired,<br>50 mg SD p.o.</td>
<td class="Rrule Toprule" align="center">Tramadol<br>M1</td>
<td class="Rrule Toprule" align="center">217 (11)<br>19.4 (12)</td>
<td class="Rrule Toprule" align="center">1.9 (16)<br>9.8 (20)</td>
<td class="Rrule Toprule" align="center">4.23 (56)<br><a href="#footnote-3" class="Sup">‡</a>
</td>
<td class="Rrule Toprule" align="center">13.3 (11)<br>18.5 (15)</td>
</tr>
<tr>
<td class="Lrule Rrule Toprule" align="left">Renal Impaired, CL<span class="Sub">cr</span>10–30 mL/min 100 mg SD i.v.</td>
<td class="Rrule Toprule" align="center">Tramadol<br>M1</td>
<td class="Rrule Toprule" align="center">
<a href="#footnote-3" class="Sup">‡</a><br><a href="#footnote-3" class="Sup">‡</a>
</td>
<td class="Rrule Toprule" align="center">
<a href="#footnote-3" class="Sup">‡</a><br><a href="#footnote-3" class="Sup">‡</a>
</td>
<td class="Rrule Toprule" align="center">4.23 (54)<br><a href="#footnote-3" class="Sup">‡</a>
</td>
<td class="Rrule Toprule" align="center">10.6 (31)<br>11.5 (40)</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule Toprule" align="left">Renal Impaired, CL<span class="Sub">cr</span>&lt;5 mL/min 100 mg SD i.v. </td>
<td class="Rrule Toprule" align="center">Tramadol<br>M1</td>
<td class="Rrule Toprule" align="center">
<a href="#footnote-3" class="Sup">‡</a><br><a href="#footnote-3" class="Sup">‡</a>
</td>
<td class="Rrule Toprule" align="center">
<a href="#footnote-3" class="Sup">‡</a><br><a href="#footnote-3" class="Sup">‡</a>
</td>
<td class="Rrule Toprule" align="center">3.73 (17)<br><a href="#footnote-3" class="Sup">‡</a>
</td>
<td class="Rrule Toprule" align="center">11.0 (29)<br>16.9 (18)</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.2.2"></a><p></p>
<h3>Food Effects</h3>
<p class="First">Oral administration of ULTRAM<span class="Sup">®</span> with food does not significantly affect its rate or extent of absorption, therefore, ULTRAM<span class="Sup">®</span> can be administered without regard to food.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.2.3"></a><p></p>
<h3>Distribution</h3>
<p class="First">The volume of distribution of tramadol was 2.6 and 2.9 liters/kg in male and female subjects, respectively, following a 100 mg intravenous dose. The binding of tramadol to human plasma proteins is approximately 20% and binding also appears to be independent of concentration up to 10 µg/mL. Saturation of plasma protein binding occurs only at concentrations outside the clinically relevant range.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.2.4"></a><p></p>
<h3>Metabolism</h3>
<p class="First">Tramadol is extensively metabolized after oral administration by a number of pathways, including CYP2D6 and CYP3A4, as well as by conjugation of parent and metabolites. Approximately 30% of the dose is excreted in the urine as unchanged drug, whereas 60% of the dose is excreted as metabolites. The remainder is excreted either as unidentified or as unextractable metabolites. The major metabolic pathways appear to be<span class="Italics"> N</span>- and<span class="Italics"> O</span>-demethylation and glucuronidation or sulfation in the liver. One metabolite (<span class="Italics">O</span>-desmethyltramadol, denoted M1) is pharmacologically active in animal models. Formation of M1 is dependent on CYP2D6 and as such is subject to inhibition, which may affect the therapeutic response (see<span class="Bold"><a href="#DI"> PRECAUTIONS, Drug Interaction</a></span>).</p>
<p>Approximately 7% of the population has reduced activity of the CYP2D6 isoenzyme of cytochrome P-450. These individuals are "poor metabolizers" of debrisoquine, dextromethorphan, tricyclic antidepressants, among other drugs. Based on a population PK analysis of Phase I studies in healthy subjects, concentrations of tramadol were approximately 20% higher in "poor metabolizers" versus "extensive metabolizers", while M1 concentrations were 40% lower. Concomitant therapy with inhibitors of CYP2D6 such as fluoxetine, paroxetine and quinidine could result in significant drug interactions.<span class="Italics"> In vitro </span>drug interaction studies in human liver microsomes indicate that inhibitors of CYP2D6 such as fluoxetine and its metabolite norfluoxetine, amitriptyline and quinidine inhibit the metabolism of tramadol to various degrees, suggesting that concomitant administration of these compounds could result in increases in tramadol concentrations and decreased concentrations of M1. The full pharmacological impact of these alterations in terms of either efficacy or safety is unknown. Concomitant use of SEROTONIN re-uptake INHIBITORS and MAO INHIBITORS may enhance the risk of adverse events, including <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> (see<span class="Bold"><a href="#WARNINGS"> WARNINGS</a></span>) and <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.2.5"></a><p></p>
<h3>Elimination</h3>
<p class="First">Tramadol is eliminated primarily through metabolism by the liver and the metabolites are eliminated primarily by the kidneys. The mean terminal plasma elimination half-lives of racemic tramadol and racemic M1 are 6.3 ± 1.4 and 7.4 ± 1.4 hours, respectively. The plasma elimination half-life of racemic tramadol increased from approximately six hours to seven hours upon multiple dosing.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.3"></a><p></p>
<h2>Special Populations</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.3.1"></a><p></p>
<h3>Renal</h3>
<p class="First"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Impaired renal function</span> results in a decreased rate and extent of excretion of tramadol and its active metabolite, M1. In patients with creatinine clearances of less than 30 mL/min, adjustment of the dosing regimen is recommended (see<span class="Bold"><a href="#DA"> DOSAGE AND ADMINISTRATION</a></span>). The total amount of tramadol and M1 removed during a 4-hour dialysis period is less than 7% of the administered dose.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.3.2"></a><p></p>
<h3>Hepatic</h3>
<p class="First">Metabolism of tramadol and M1 is reduced in patients with advanced cirrhosis of the liver, resulting in both a larger area under the concentration time curve for tramadol and longer tramadol and M1 elimination half-lives (13 hrs. for tramadol and 19 hrs. for M1). In cirrhotic patients, adjustment of the dosing regimen is recommended (see<span class="Bold"><a href="#DA"> DOSAGE AND ADMINISTRATION</a></span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.3.3"></a><p></p>
<h3>Geriatric</h3>
<p class="First">Healthy elderly subjects aged 65 to 75 years have plasma tramadol concentrations and elimination half-lives comparable to those observed in healthy subjects less than 65 years of age. In subjects over 75 years, maximum serum concentrations are elevated (208 vs. 162 ng/mL) and the elimination half-life is prolonged (7 vs. 6 hours) compared to subjects 65 to 75 years of age. Adjustment of the daily dose is recommended for patients older than 75 years (see<span class="Bold"><a href="#DA"> DOSAGE AND ADMINISTRATION</a></span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.3.4"></a><p></p>
<h3>Gender</h3>
<p class="First">The absolute bioavailability of tramadol was 73% in males and 79% in females. The plasma clearance was 6.4 mL/min/kg in males and 5.7 mL/min/kg in females following a 100 mg IV dose of tramadol. Following a single oral dose, and after adjusting for body weight, females had a 12% higher peak tramadol concentration and a 35% higher area under the concentration-time curve compared to males. The clinical significance of this difference is unknown.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="section-4"></a><p></p>
<h1>CLINICAL STUDIES</h1>
<p class="First">ULTRAM<span class="Sup">®</span> has been given in single oral doses of 50, 75 and 100 mg to patients with <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> following surgical procedures and <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> following oral surgery (extraction of impacted molars).</p>
<p>In single-dose models of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> following oral surgery, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> relief was demonstrated in some patients at doses of 50 mg and 75 mg. A dose of 100 mg ULTRAM<span class="Sup">®</span> tended to provide <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> superior to codeine sulfate 60 mg, but it was not as effective as the combination of aspirin 650 mg with codeine phosphate 60 mg.</p>
<p>ULTRAM<span class="Sup">®</span> has been studied in three long-term controlled trials involving a total of 820 patients, with 530 patients receiving ULTRAM<span class="Sup">®</span>. Patients with a variety of chronic painful conditions were studied in double-blind trials of one to three months duration. Average daily doses of approximately 250 mg of ULTRAM<span class="Sup">®</span> in divided doses were generally comparable to five doses of acetaminophen 300 mg with codeine phosphate 30 mg (TYLENOL<span class="Sup">®</span> with Codeine #3) daily, five doses of aspirin 325 mg with codeine phosphate 30 mg daily, or two to three doses of acetaminophen 500 mg with oxycodone hydrochloride 5 mg (TYLOX<span class="Sup">®</span>) daily.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-4.1"></a><p></p>
<h2>Titration Trials</h2>
<p class="First">In a randomized, blinded clinical study with 129 to 132 patients per group, a 10-day titration to a daily ULTRAM<span class="Sup">®</span> dose of 200 mg (50 mg four times per day), attained in 50 mg increments every 3 days, was found to result in fewer discontinuations due to <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> or <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span> than titration over only 4 days or no titration. In a second study with 54 to 59 patients per group, patients who had <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> when titrated over 4 days were randomized to re-initiate ULTRAM<span class="Sup">®</span> therapy using slower titration rates.</p>
<p>A 16-day titration schedule, starting with 25 mg qAM and using additional doses in 25 mg increments every third day to 100 mg/day (25 mg four times per day), followed by 50 mg increments in the total daily dose every third day to 200 mg/day (50 mg four times per day), resulted in fewer discontinuations due to <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> and fewer discontinuations due to any cause than did a 10-day titration schedule.</p>
<p><span class="Bold">Figure 2:</span></p>
<div class="Figure"><img alt="Figure 2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=288ddb7b-29e4-46c7-9d84-38a188231710&amp;name=ultram-03.jpg"></div>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-5"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">ULTRAM<span class="Sup">®</span> is indicated for the management of moderate to moderately severe <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> in adults.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-6"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">ULTRAM<span class="Sup">®</span> should not be administered to patients who have previously demonstrated <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to tramadol, any other component of this product or opioids. ULTRAM<span class="Sup">®</span> is contraindicated in any situation where opioids are contraindicated, including acute <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span> with any of the following: alcohol, hypnotics, narcotics, centrally acting analgesics, opioids or psychotropic drugs. ULTRAM<span class="Sup">®</span> may worsen central nervous system and <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> in these patients.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="section-7"></a><p></p>
<h1>WARNINGS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.1"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizure</span> Risk</h2>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span> have been reported in patients receiving ULTRAM<span class="Sup">®</span> within the recommended dosage range. Spontaneous post-marketing reports indicate that <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> risk is increased with doses of ULTRAM<span class="Sup">®</span> above the recommended range. Concomitant use of ULTRAM<span class="Sup">®</span> increases the <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> risk in patients taking:</span></p>
<ul class="Disc">
<li><span class="Bold">Selective serotonin re-uptake inhibitors (SSRI antidepressants or <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorectics</span>),</span></li>
<li><span class="Bold">Tricyclic antidepressants (TCAs), and other tricyclic compounds (e.g., cyclobenzaprine, promethazine, etc.), or</span></li>
<li><span class="Bold">Other opioids.</span></li>
</ul>
<p><span class="Bold">Administration of ULTRAM<span class="Sup">®</span> may enhance the <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> risk in patients taking:</span></p>
<ul class="Disc">
<li><span class="Bold">MAO inhibitors (see also<a href="#usewithmao"> WARNINGS, Use With MAO Inhibitors and Serotonin Re-Uptake Inhibitors</a>),</span></li>
<li><span class="Bold">Neuroleptics, or</span></li>
<li><span class="Bold">Other drugs that reduce the <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> threshold.</span></li>
</ul>
<p><span class="Bold">Risk of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> may also increase in patients with <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span>, those with a history of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, or in patients with a recognized risk for <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> (such as head <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span>, <span class="product-label-link" type="condition" conceptid="436670" conceptname="Metabolic disease">metabolic disorders</span>, alcohol and drug withdrawal, CNS <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>). In ULTRAM<span class="Sup">®</span> <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, naloxone administration may increase the risk of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span>.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.2"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">Suicide</span> Risk</h2>
<ul class="Disc">
<li><span class="Bold">Do not prescribe ULTRAM<span class="Sup">®</span> for patients who are suicidal or addiction-prone.</span></li>
<li><span class="Bold">Prescribe ULTRAM<span class="Sup">®</span> Tablets with caution for patients who are taking tranquilizers or antidepressant drug and patients who use alcohol in excess and who suffer from <span class="product-label-link" type="condition" conceptid="4305081" conceptname="Emotional problems">emotional disturbance</span> or <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>.</span></li>
</ul>
<p class="First">The judicious prescribing of tramadol is essential to the safe use of this drug. With patients who are depressed or suicidal, consideration should be given to the use of non-narcotic analgesics.</p>
<p>Tramadol-related <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> have occurred in patients with previous histories of <span class="product-label-link" type="condition" conceptid="4305081" conceptname="Emotional problems">emotional disturbances</span> or <span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">suicidal ideation</span> or attempts as well as histories of misuse of tranquilizers, alcohol, and other CNS-active drugs (see<span class="Bold"><a href="#riskofoverdosage"> WARNINGS, Risk of Overdosage</a></span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.3"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin Syndrome</span> Risk</h2>
<p class="First"><span class="Bold">The development of a potentially life-threatening <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span> may occur with the use of tramadol products, including ULTRAM<span class="Sup">®</span>, particularly with concomitant use of serotonergic drugs such as SSRIs, SNRIs, TCAs, MAOIs, and triptans, with drugs which impair metabolism of serotonin (including MAOIs), and with drugs which impair metabolism of tramadol (CYP2D6 and CYP3A4 inhibitors).  This may occur within the recommended dose (see<a href="#Pharmacokinetics"> CLINICAL PHARMACOLOGY, Pharmacokinetics</a>).</span></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin syndrome</span> may include mental-status changes (e.g., <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>), <span class="product-label-link" type="condition" conceptid="434633" conceptname="Disorder of autonomic nervous system">autonomic instability</span> (e.g., <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="4354255" conceptname="Labile blood pressure">labile blood pressure</span>, <span class="product-label-link" type="condition" conceptid="4178904" conceptname="Body temperature above reference range">hyperthermia</span>), neuromuscular aberrations (e.g., <span class="product-label-link" type="condition" conceptid="4313132" conceptname="Hyperreflexia">hyperreflexia</span>, <span class="product-label-link" type="condition" conceptid="441417" conceptname="Incoordination">incoordination</span>) and/or <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal symptoms</span> (e.g., <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>).</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.4"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid Reactions</span></h2>
<p class="First">Serious and rarely fatal <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span> have been reported in patients receiving therapy with ULTRAM<span class="Sup">®</span>. When these events do occur it is often following the first dose. Other reported <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> include <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span>, <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span> and <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>. Patients with a history of <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span> to codeine and other opioids may be at increased risk and therefore should not receive ULTRAM<span class="Sup">®</span> (see<span class="Bold"><a href="#CONTRAINDICATIONS"> CONTRAINDICATIONS</a></span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.5"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory Depression</span></h2>
<p class="First">Administer ULTRAM<span class="Sup">®</span> cautiously in patients at risk for <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>. In these patients alternative non-opioid analgesics should be considered. When large doses of ULTRAM<span class="Sup">®</span> are administered with anesthetic medications or alcohol, <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> may result. <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory depression</span> should be treated as an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>. If naloxone is to be administered, use cautiously because it may precipitate <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> (see<span class="Bold"><a href="#seizurerisk"> WARNINGS, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizure</span> Risk </a></span>and<span class="Bold"><a href="#OVERDOSAGE"> OVERDOSAGE</a></span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.6"></a><p></p>
<h2>Interaction With Central Nervous System (CNS) Depressants</h2>
<p class="First">ULTRAM<span class="Sup">®</span> should be used with caution and in reduced dosages when administered to patients receiving CNS depressants such as alcohol, opioids, anesthetic agents, narcotics, phenothiazines, tranquilizers or sedative hypnotics. ULTRAM<span class="Sup">®</span> increases the risk of CNS and <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> in these patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.7"></a><p></p>
<h2>Interactions With Alcohol and Drugs of Abuse</h2>
<p class="First">Tramadol may be expected to have additive effects when used in conjunction with alcohol, other opioids, or illicit drugs that cause central nervous system <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.8"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">Increased Intracranial Pressure</span> or Head <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">Trauma</span></h2>
<p class="First">ULTRAM<span class="Sup">®</span> should be used with caution in patients with <span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">increased intracranial pressure</span> or <span class="product-label-link" type="condition" conceptid="375415" conceptname="Injury of head">head injury</span>. The respiratory depressant effects of opioids include <span class="product-label-link" type="condition" conceptid="4135927" conceptname="Carbon dioxide">carbon dioxide</span> retention and secondary elevation of cerebrospinal fluid pressure, and may be markedly exaggerated in these patients. Additionally, pupillary changes (<span class="product-label-link" type="condition" conceptid="435279" conceptname="Tonic pupillary reaction">miosis</span>) from tramadol may obscure the existence, extent, or course of intracranial pathology. Clinicians should also maintain a high index of suspicion for adverse drug reaction when evaluating altered mental status in these patients if they are receiving ULTRAM<span class="Sup">®</span> (see<span class="Bold"><a href="#respiratorydepression"> WARNINGS, <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory Depression</span></a></span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.9"></a><p></p>
<h2>Use in Ambulatory Patients</h2>
<p class="First">ULTRAM<span class="Sup">®</span> may impair the mental and or physical abilities required for the performance of potentially hazardous tasks such as driving a car or operating machinery. The patient using this drug should be cautioned accordingly.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.10"></a><p></p>
<h2>Use With MAO Inhibitors and Serotonin Re-uptake Inhibitors</h2>
<p class="First">Use ULTRAM<span class="Sup">®</span> with great caution in patients taking monoamine oxidase inhibitors. Animal studies have shown increased <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> with combined administration. Concomitant use of ULTRAM<span class="Sup">®</span> with MAO inhibitors or SSRI's increases the risk of adverse events, including <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> and <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.11"></a><p></p>
<h2>Misuse, Abuse and Diversion</h2>
<p class="First">Tramadol has mu-opioid agonist activity. ULTRAM<span class="Sup">®</span> can be sought by drug abusers and people with addiction disorders and may be subject to criminal diversion.</p>
<p>The possibility of illegal or illicit use should be considered when prescribing or dispensing ULTRAM<span class="Sup">®</span>  in situations where the physician or pharmacist is concerned about an increased risk of misuse, abuse, or diversion. Misuse or abuse poses a significant risk to the abuser that could result in <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> (see<span class="Bold"><a href="#drugs"> DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span> </a></span>and<span class="Bold"><a href="#OVERDOSAGE"> OVERDOSAGE</a></span>).</p>
<p>Concerns about abuse, addiction, and diversion should not prevent the proper management of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>. The development of addiction to opioid analgesics in properly managed patients with <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> has been reported to be rare. However, data are not available to establish the true incidence of addiction in <span class="product-label-link" type="condition" conceptid="436096" conceptname="Chronic pain">chronic pain</span> patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.12"></a><p></p>
<h2>Risk of Overdosage</h2>
<p class="First">Patients taking tramadol should be warned not to exceed the dose recommended by their physician. Tramadol products in excessive doses, either alone or in combination with other CNS depressants, including alcohol, are a cause of drug-related <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span>. Patients should be cautioned about the concomitant use of tramadol products and alcohol because of potentially serious CNS additive effects of these agents. Because of its added depressant effects, tramadol should be prescribed with caution for those patients whose medical condition requires the concomitant administration of sedatives, tranquilizers, muscle relaxants, antidepressants, or other CNS depressant drugs. Patients should be advised of the additive depressant effects of these combinations.</p>
<p>Serious potential consequences of overdosage with ULTRAM<span class="Sup">®</span> (tramadol hydrochloride) tablets are central nervous system <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Some <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> have occurred as a consequence of the accidental ingestion of excessive quantities of tramadol alone or in combination with other drugs. In treating an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, primary attention should be given to maintaining adequate ventilation along with general supportive treatment (see<span class="Bold"><a href="#OVERDOSAGE"> OVERDOSAGE</a></span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.13"></a><p></p>
<h2>Withdrawal</h2>
<p class="First">Withdrawal symptoms may occur if ULTRAM<span class="Sup">®</span> is discontinued abruptly (see also<span class="Bold"><a href="#drugs"> DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></a></span>). Reported symptoms have included <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">rigors</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, upper respiratory symptoms, <span class="product-label-link" type="condition" conceptid="4224957" conceptname="Piloerection">piloerection</span>, and rarely <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>. Other symptoms that have been reported less frequently with ULTRAM<span class="Sup">®</span> discontinuation include <span class="product-label-link" type="condition" conceptid="4021498" conceptname="Panic attack">panic attacks</span>, severe <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, and <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesias</span>. Clinical experience suggests that withdrawal symptoms may be avoided by tapering ULTRAM<span class="Sup">®</span> at the time of discontinuation.</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-8"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1"></a><p></p>
<h2>Acute Abdominal Conditions</h2>
<p class="First">The administration of ULTRAM<span class="Sup">®</span> may complicate the clinical assessment of patients with acute abdominal conditions.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.2"></a><p></p>
<h2>Use in Renal and <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Disease</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Impaired renal function</span> results in a decreased rate and extent of excretion of tramadol and its active metabolite, M1. In patients with creatinine clearances of less than 30 mL/min, dosing reduction is recommended (see<span class="Bold"><a href="#DA"> DOSAGE AND ADMINISTRATION</a></span>). Metabolism of tramadol and M1 is reduced in patients with advanced cirrhosis of the liver. In cirrhotic patients, dosing reduction is recommended (see<span class="Bold"><a href="#DA"> DOSAGE AND ADMINISTRATION</a></span>).</p>
<p>With the prolonged half-life in these conditions, achievement of steady-state is delayed, so that it may take several days for elevated plasma concentrations to develop.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-8.3"></a><p></p>
<h2>Information for Patients</h2>
<ul class="Disc">
<li>Patients should be informed that ULTRAM<span class="Sup">®</span> may cause <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> and/or <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span> with concomitant use of serotonergic agents (including SSRIs, SNRIs, and triptans) or drugs that significantly reduce the metabolic clearance of tramadol.</li>
<li>ULTRAM<span class="Sup">®</span> may impair mental or physical abilities required for the performance of potentially hazardous tasks such as driving a car or operating machinery.</li>
<li>ULTRAM<span class="Sup">®</span> should not be taken with alcohol containing beverages.</li>
<li>ULTRAM<span class="Sup">®</span> should be used with caution when taking medications such as tranquilizers, hypnotics or other opiate containing analgesics.</li>
<li>The patient should be instructed to inform the physician if they are pregnant, think they might become pregnant, or are trying to become pregnant (see<span class="Bold"><a href="#Labor"> PRECAUTIONS, Labor and Delivery</a></span>).</li>
<li>The patient should understand the single-dose and 24-hour dose limit and the time interval between doses, since exceeding these recommendations can result in <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. </li>
</ul>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section-8.4"></a><p></p>
<h2>Drug Interactions</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.4.1"></a><p></p>
<h3>CYP2D6 and CYP3A4 Inhibitors</h3>
<p class="First">Concomitant administration of CYP2D6 and/or CYP3A4 inhibitors (see<span class="Bold"><a href="#Pharmacokinetics"> CLINICAL PHARMACOLOGY, Pharmacokinetics</a></span>), such as quinidine, fluoxetine, paroxetine and amitriptyline (CYP2D6 inhibitors), and ketoconazole and erythromycin (CYP3A4 inhibitors), may reduce metabolic clearance of tramadol increasing the risk for serious adverse events including <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> and <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.4.2"></a><p></p>
<h3>Serotonergic Drugs</h3>
<p class="First">There have been postmarketing reports of <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span> with use of tramadol and SSRIs/SNRIs or MAOIs and α2-adrenergic blockers. Caution is advised when ULTRAM<span class="Sup">®</span> is co-administered with other drugs that may affect the serotonergic neurotransmitter systems, such as SSRIs, MAOIs, triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, or St. John's Wort. If concomitant treatment of ULTRAM<span class="Sup">®</span> with a drug affecting the serotonergic neurotransmitter system is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases (see<span class="Bold"><a href="#serotoninsyndrome"> WARNINGS, <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin Syndrome</span> Risk</a></span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.4.3"></a><p></p>
<h3>Triptans</h3>
<p class="First">Based on the mechanism of action of tramadol and the potential for <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">serotonin syndrome</span>, caution is advised when ULTRAM<span class="Sup">®</span> is co-administered with a triptan. If concomitant treatment of ULTRAM<span class="Sup">®</span> with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases (see<span class="Bold"><a href="#Serotoninsyndrome"> WARNINGS, <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin Syndrome</span> Risk</a></span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.4.4"></a><p></p>
<h3>Use With Carbamazepine</h3>
<p class="First">Patients taking<span class="Bold"> carbamazepine </span>may have a significantly reduced <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesic effect</span> of ULTRAM<span class="Sup">®</span>. Because carbamazepine increases tramadol metabolism and because of the <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> risk associated with tramadol, concomitant administration of ULTRAM<span class="Sup">®</span> and carbamazepine is not recommended.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.4.5"></a><p></p>
<h3>Use With Quinidine</h3>
<p class="First">Tramadol is metabolized to M1 by CYP2D6.<span class="Bold"> Quinidine </span>is a selective inhibitor of that isoenzyme, so that concomitant administration of quinidine and ULTRAM<span class="Sup">®</span> results in increased concentrations of tramadol and reduced concentrations of M1. The clinical consequences of these findings are unknown.<span class="Italics"> In vitro </span>drug interaction studies in human liver microsomes indicate that tramadol has no effect on quinidine metabolism.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.4.6"></a><p></p>
<h3>Potential for Other Drugs to Affect Tramadol</h3>
<p class="First"><span class="Italics">In vitro </span>drug interaction studies in human liver microsomes indicate that concomitant administration with inhibitors of CYP2D6 such as fluoxetine, paroxetine, and amitriptyline could result in some inhibition of the metabolism of tramadol. Administration of CYP3A4 inhibitors, such as ketoconazole and erythromycin, or inducers, such as rifampin and St. John's Wort, with ULTRAM<span class="Sup">®</span> may affect the metabolism of tramadol leading to altered tramadol exposure.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.4.7"></a><p></p>
<h3>Potential for Tramadol to Affect Other Drugs</h3>
<p class="First"><span class="Italics">In vitro </span>studies indicate that tramadol is unlikely to inhibit the CYP3A4-mediated metabolism of other drugs when tramadol is administered concomitantly at therapeutic doses. Tramadol does not appear to induce its own metabolism in humans, since observed maximal plasma concentrations after multiple oral doses are higher than expected based on single-dose data. Tramadol is a mild inducer of selected drug metabolism pathways measured in animals.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.4.8"></a><p></p>
<h3>Use With Cimetidine</h3>
<p class="First">Concomitant administration of ULTRAM<span class="Sup">®</span> with<span class="Bold"> cimetidine </span>does not result in clinically significant changes in tramadol pharmacokinetics. Therefore, no alteration of the ULTRAM<span class="Sup">®</span> dosage regimen is recommended.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.4.9"></a><p></p>
<h3>Use With Digoxin and Warfarin</h3>
<p class="First">Post-marketing surveillance has revealed rare reports of <span class="product-label-link" type="condition" conceptid="433667" conceptname="Poisoning by tetanus vaccine">digoxin toxicity</span> and alteration of warfarin effect, including elevation of <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> times.</p>
</div>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="section-8.5"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">A slight, but statistically significant, increase in two common murine tumors, pulmonary and hepatic, was observed in a mouse carcinogenicity study, particularly in aged mice. Mice were dosed orally up to 30 mg/kg (90 mg/m<span class="Sup">2</span> or 0.36 times the maximum daily human dosage of 246 mg/m<span class="Sup">2</span>) for approximately two years, although the study was not done with the Maximum Tolerated Dose. This finding is not believed to suggest risk in humans. No such finding occurred in a rat carcinogenicity study (dosing orally up to 30 mg/kg, 180 mg/m<span class="Sup">2</span>, or 0.73 times the maximum daily human dosage).</p>
<p>Tramadol was not mutagenic in the following assays: Ames<span class="Italics"> <span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span> </span>microsomal activation test, CHO/HPRT mammalian cell assay, mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> assay (in the absence of metabolic activation), dominant lethal mutation tests in mice, chromosome aberration test in Chinese hamsters, and bone marrow micronucleus tests in mice and Chinese hamsters. Weakly mutagenic results occurred in the presence of metabolic activation in the mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> assay and micronucleus test in rats. Overall, the weight of evidence from these tests indicates that tramadol does not pose a genotoxic risk to humans.</p>
<p>No effects on fertility were observed for tramadol at oral dose levels up to 50 mg/kg (300 mg/m<span class="Sup">2</span>) in male rats and 75 mg/kg (450 mg/m<span class="Sup">2</span>) in female rats. These dosages are 1.2 and 1.8 times the maximum daily human dosage of 246 mg/m<span class="Sup">2</span>, respectively.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="section-8.6"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="section-8.6.1"></a><p></p>
<h3>Teratogenic Effects</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.6.1.1"></a><p></p>
<h4>Pregnancy Category C</h4>
<p class="First">Tramadol has been shown to be embryotoxic and fetotoxic in mice, (120 mg/kg or 360 mg/m<span class="Sup">2</span>), rats (≥25 mg/kg or 150 mg/m<span class="Sup">2</span>) and rabbits (≥75 mg/kg or 900 mg/m<span class="Sup">2</span>) at maternally toxic dosages, but was not teratogenic at these dose levels. These dosages on a mg/m<span class="Sup">2</span> basis are 1.4, ≥0.6, and ≥3.6 times the maximum daily human dosage (246 mg/m<span class="Sup">2</span>) for mouse, rat and rabbit, respectively.</p>
<p>No drug-related teratogenic effects were observed in progeny of mice (up to 140 mg/kg or 420 mg/m<span class="Sup">2</span>), rats (up to 80 mg/kg or 480 mg/m<span class="Sup">2</span>) or rabbits (up to 300 mg/kg or 3600 mg/m<span class="Sup">2</span>) treated with tramadol by various routes. Embryo and fetal toxicity consisted primarily of decreased fetal weights, skeletal ossification and increased supernumerary ribs at maternally toxic dose levels. Transient delays in developmental or behavioral parameters were also seen in pups from rat dams allowed to deliver. Embryo and fetal lethality were reported only in one rabbit study at 300 mg/kg (3600 mg/m<span class="Sup">2</span>), a dose that would cause extreme maternal toxicity in the rabbit. The dosages listed for mouse, rat and rabbit are 1.7, 1.9 and 14.6 times the maximum daily human dosage (246 mg/m<span class="Sup">2</span>), respectively.</p>
</div>
</div>
<div class="Section" data-sectionCode="34078-6">
<a name="section-8.6.2"></a><p></p>
<h3>Non-teratogenic Effects</h3>
<p class="First">Tramadol was evaluated in peri- and post-natal studies in rats. Progeny of dams receiving oral (gavage) dose levels of 50 mg/kg (300 mg/m<span class="Sup">2</span> or 1.2 times the maximum daily human tramadol dosage) or greater had decreased weights, and pup survival was decreased early in lactation at 80 mg/kg (480 mg/m<span class="Sup">2</span> or 1.9 and higher the maximum daily human dose).</p>
<p>There are no adequate and well-controlled studies in pregnant women. ULTRAM<span class="Sup">®</span> should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. <span class="product-label-link" type="condition" conceptid="380533" conceptname="Convulsions in the newborn">Neonatal seizures</span>, neonatal withdrawal syndrome, <span class="product-label-link" type="condition" conceptid="4079844" conceptname="Fetal death">fetal death</span> and still birth have been reported during post-marketing.</p>
</div>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="section-8.7"></a><p></p>
<h2>Labor and Delivery</h2>
<p class="First">ULTRAM<span class="Sup">®</span> should not be used in pregnant women prior to or during labor unless the potential benefits outweigh the risks. Safe use in pregnancy has not been established. Chronic use during pregnancy may lead to physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> and post-partum withdrawal symptoms in the newborn (see<span class="Bold"><a href="#Drugs"> DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></a></span>). Tramadol has been shown to cross the placenta. The mean ratio of serum tramadol in the umbilical veins compared to maternal veins was 0.83 for 40 women given tramadol during labor.</p>
<p>The effect of ULTRAM<span class="Sup">®</span>, if any, on the later growth, development, and functional maturation of the child is unknown.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-8.8"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">ULTRAM<span class="Sup">®</span> is not recommended for obstetrical preoperative medication or for post-delivery <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> in nursing mothers because its safety in infants and newborns has not been studied. Following a single IV 100 mg dose of tramadol, the cumulative excretion in breast milk within 16 hours postdose was 100 µg of tramadol (0.1% of the maternal dose) and 27 µg of M1.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-8.9"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">The safety and efficacy of ULTRAM<span class="Sup">®</span> in patients under 16 years of age have not been established. The use of ULTRAM<span class="Sup">®</span> in the pediatric population is not recommended.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="section-8.10"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal or cardiac function and of concomitant disease or other drug therapy. In patients over 75 years of age, daily doses in excess of 300 mg are not recommended (see<span class="Bold"><a href="#CP"> CLINICAL PHARMACOLOGY </a></span>and<span class="Bold"><a href="#DA"> DOSAGE AND ADMINISTRATION</a></span>).</p>
<p>A total of 455 elderly (65 years of age or older) subjects were exposed to ULTRAM<span class="Sup">®</span> in controlled clinical trials. Of those, 145 subjects were 75 years of age and older.</p>
<p>In studies including geriatric patients, treatment-limiting adverse events were higher in subjects over 75 years of age compared to those under 65 years of age. Specifically, 30% of those over 75 years of age had gastrointestinal treatment-limiting adverse events compared to 17% of those under 65 years of age. <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span> resulted in discontinuation of treatment in 10% of those over 75.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-9"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">ULTRAM<span class="Sup">®</span> was administered to 550 patients during the double-blind or open-label extension periods in U.S. studies of chronic nonmalignant <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>. Of these patients, 375 were 65 years old or older. Table 2 reports the cumulative incidence rate of adverse reactions by 7, 30 and 90 days for the most frequent reactions (5% or more by 7 days). The most frequently reported events were in the central nervous system and gastrointestinal system. Although the reactions listed in the table are felt to be probably related to ULTRAM<span class="Sup">®</span> administration, the reported rates also include some events that may have been due to underlying disease or concomitant medication. The overall incidence rates of adverse experiences in these trials were similar for ULTRAM<span class="Sup">®</span> and the active control groups, TYLENOL<span class="Sup">®</span> with Codeine #3 (acetaminophen 300 mg with codeine phosphate 30 mg), and aspirin 325 mg with codeine phosphate 30 mg, however, the rates of withdrawals due to adverse events appeared to be higher in the ULTRAM<span class="Sup">®</span> groups.</p>
<table width="100%">
<caption><span>Table 2:	Cumulative Incidence of Adverse Reactions for ULTRAM<span class="Sup">®</span> in Chronic Trials of Nonmalignant <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> (N=427)</span></caption>
<col align="left" valign="top" width="25%">
<col align="left" valign="top" width="25%">
<col align="left" valign="top" width="25%">
<col align="left" valign="top" width="25%">
<thead><tr class="First Last">
<th class="Lrule" align="left"></th>
<th align="left">Up to 7 Days</th>
<th align="left">Up to 30 Days</th>
<th class="Rrule" align="left">Up to 90 Days</th>
</tr></thead>
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-5" href="#footnote-reference-5">*</a></dt>
<dd>"CNS Stimulation" is a composite of <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="4287788" conceptname="Spasticity">spasticity</span>, <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">euphoria</span>, <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">emotional lability</span> and <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span></dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span>/<span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">Vertigo</span></td>
<td align="left">26%</td>
<td align="left">31%</td>
<td class="Rrule" align="left">33%</td>
</tr>
<tr>
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td align="left">24%</td>
<td align="left">34%</td>
<td class="Rrule" align="left">40%</td>
</tr>
<tr>
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></td>
<td align="left">24%</td>
<td align="left">38%</td>
<td class="Rrule" align="left">46%</td>
</tr>
<tr>
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td align="left">18%</td>
<td align="left">26%</td>
<td class="Rrule" align="left">32%</td>
</tr>
<tr>
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span></td>
<td align="left">16%</td>
<td align="left">23%</td>
<td class="Rrule" align="left">	25%</td>
</tr>
<tr>
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td align="left">9%</td>
<td align="left">13%</td>
<td class="Rrule" align="left">17%</td>
</tr>
<tr>
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span></td>
<td align="left">8%</td>
<td align="left">10%</td>
<td class="Rrule" align="left">11%</td>
</tr>
<tr>
<td class="Lrule" align="left">"CNS Stimulation"<a name="footnote-reference-5" href="#footnote-5" class="Sup">*</a>
</td>
<td align="left">7%</td>
<td align="left">11%</td>
<td class="Rrule" align="left">14%</td>
</tr>
<tr>
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span></td>
<td align="left">6%</td>
<td align="left">11%</td>
<td class="Rrule" align="left">12%</td>
</tr>
<tr>
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">Sweating</span></td>
<td align="left">6%</td>
<td align="left">7%</td>
<td class="Rrule" align="left">9%</td>
</tr>
<tr>
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span></td>
<td align="left">5%</td>
<td align="left">9%</td>
<td class="Rrule" align="left">13%</td>
</tr>
<tr>
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry Mouth</span></td>
<td align="left">5%</td>
<td align="left">9%</td>
<td class="Rrule" align="left">10%</td>
</tr>
<tr class="Last">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td align="left">5%</td>
<td align="left">6%</td>
<td class="Rrule" align="left">10%</td>
</tr>
</tbody>
</table>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.1"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Incidence 1% to less than 5% possibly causally related</span>: the following lists adverse reactions that occurred with an incidence of 1% to less than 5% in clinical trials, and for which the possibility of a causal relationship with ULTRAM<span class="Sup">®</span> exists.</p>
<p><span class="Bold">Body as a Whole: </span><span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">Malaise</span>.</p>
<p><span class="Bold">Cardiovascular: </span>Vasodilation.</p>
<p><span class="Bold">Central Nervous System: </span><span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">Confusion</span>, <span class="product-label-link" type="condition" conceptid="441417" conceptname="Incoordination">Coordination disturbance</span>, <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">Euphoria</span>, <span class="product-label-link" type="condition" conceptid="435279" conceptname="Tonic pupillary reaction">Miosis</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">Nervousness</span>, <span class="product-label-link" type="condition" conceptid="435524" conceptname="Sleep disorder">Sleep disorder</span>.</p>
<p><span class="Bold">Gastrointestinal: </span><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span>, <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">Flatulence</span>.</p>
<p><span class="Bold">Musculoskeletal: </span><span class="product-label-link" type="condition" conceptid="4208994" conceptname="Increased muscle tone">Hypertonia</span>.</p>
<p><span class="Bold">Skin: </span><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span>.</p>
<p><span class="Bold">Special Senses: </span><span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">Visual disturbance</span>.</p>
<p><span class="Bold">Urogenital: </span><span class="product-label-link" type="condition" conceptid="439082" conceptname="Menopausal syndrome">Menopausal symptoms</span>, <span class="product-label-link" type="condition" conceptid="4012368" conceptname="Increased frequency of urination">Urinary frequency</span>, <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">Urinary retention</span>.</p>
<p><span class="Italics">Incidence less than 1%, possibly causally related: </span>the following lists adverse reactions that occurred with an incidence of less than 1% in clinical trials of tramadol and/or reported in post-marketing experience with tramadol-containing products.</p>
<p><span class="Bold">Body as a Whole: </span><span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">Accidental injury</span>, <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic reaction</span>, <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span>, <span class="product-label-link" type="condition" conceptid="4092095" conceptname="Planning suicide">Suicidal tendency</span>, <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">Weight loss</span>, <span class="product-label-link" type="condition" conceptid="4154707" conceptname="Serotonin syndrome">Serotonin syndrome</span> (mental status change, <span class="product-label-link" type="condition" conceptid="4313132" conceptname="Hyperreflexia">hyperreflexia</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">shivering</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">diaphoresis</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> and <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>).</p>
<p><span class="Bold">Cardiovascular: </span><span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">Orthostatic hypotension</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">Syncope</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">Tachycardia</span>.</p>
<p><span class="Bold">Central Nervous System: </span><span class="product-label-link" type="condition" conceptid="437643" conceptname="Abnormal gait">Abnormal gait</span>, <span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">Amnesia</span>, Cognitive dysfunction, <span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">Delirium</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span>, Difficulty in concentration, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">Hallucinations</span>, <span class="product-label-link" type="condition" conceptid="372604" conceptname="Movement disorder">Movement disorder</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">Paresthesia</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizure</span> (see<span class="Bold"><a href="#WARNINGS"> WARNINGS</a></span>), Speech disorder, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">Tremor</span>.</p>
<p><span class="Bold">Metabolism and Nutrition Disorders:</span> Cases of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> have been reported very rarely in patients taking tramadol. Most reports were in patients with predisposing risk factors, including <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> or <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>, or in elderly patients.</p>
<p><span class="Bold">Respiratory: </span><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span>.</p>
<p><span class="Bold">Skin: </span><span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>/<span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">Toxic epidermal necrolysis</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">Urticaria</span>, <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Vesicles</span>.</p>
<p><span class="Bold">Special Senses: </span><span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">Dysgeusia</span>, <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">Mydriasis</span>.</p>
<p><span class="Bold">Urogenital: </span><span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">Dysuria</span>, <span class="product-label-link" type="condition" conceptid="196471" conceptname="Puberty bleeding">Menstrual disorder</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.2"></a><p></p>
<h2></h2>
<p class="First"><span class="Italics">Other adverse experiences, causal relationship unknown</span>: A variety of other adverse events were reported infrequently in patients taking ULTRAM<span class="Sup">®</span> during clinical trials and/or reported in post-marketing experience. A causal relationship between ULTRAM<span class="Sup">®</span> and these events has not been determined. However, the most significant events are listed below as alerting information to the physician.</p>
<p><span class="Bold">Cardiovascular: </span><span class="product-label-link" type="condition" conceptid="320536" conceptname="Electrocardiogram abnormal">Abnormal ECG</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span>, <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">Myocardial ischemia</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">Palpitations</span>, <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">Pulmonary edema</span>, <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">Pulmonary embolism</span>.</p>
<p><span class="Bold">Central Nervous System: </span><span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">Migraine</span>.</p>
<p><span class="Bold">Gastrointestinal: </span><span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">Gastrointestinal bleeding</span>, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">Hepatitis</span>, <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">Stomatitis</span>, <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Liver failure</span>.</p>
<p><span class="Bold">Laboratory Abnormalities: </span>Creatinine increase, Elevated liver enzymes, Hemoglobin decrease, <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">Proteinuria</span>.</p>
<p><span class="Bold">Sensory: </span><span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">Cataracts</span>, <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">Deafness</span>, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">Tinnitus</span>. </p>
</div>
</div>
<div class="Section" data-sectionCode="42227-9">
<a name="section-10"></a><p></p>
<h1>DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></h1>
<div class="Section" data-sectionCode="34085-1">
<a name="section-10.1"></a><p></p>
<h2>Controlled Substance</h2>
<p class="First">ULTRAM<span class="Sup">®</span> (tramadol hydrochloride) Tablets are classified as a Schedule IV controlled substance.</p>
</div>
<div class="Section" data-sectionCode="34086-9">
<a name="section-10.2"></a><p></p>
<h2>Abuse</h2>
<p class="First"><span class="Bold">Tramadol has mu-opioid agonist activity. ULTRAM<span class="Sup">®</span> can be abused and may be subject to criminal diversion.</span></p>
<p>Addiction is a primary, chronic, neurobiologic disease, with genetic, psychosocial, and environmental factors influencing its development and manifestations. <span class="product-label-link" type="condition" conceptid="440069" conceptname="Drug dependence">Drug addiction</span> is characterized by behaviors that include one or more of the following: impaired control over drug use, compulsive use, use for non-medical purposes, and continued use despite harm or risk of harm, and craving. <span class="product-label-link" type="condition" conceptid="440069" conceptname="Drug dependence">Drug addiction</span> is a treatable disease, utilizing a multi-disciplinary approach, but relapse is common.</p>
<p>"Drug-seeking" behavior is very common in addicts and drug abusers. Drug-seeking tactics include emergency calls or visits near the end of office hours, refusal to undergo appropriate examination, testing or referral, repeated "loss" of prescriptions, tampering with prescriptions and reluctance to provide prior medical records or contact information for other treating physician(s). "Doctor shopping" to obtain additional prescriptions is common among drug abusers and people suffering from untreated addiction.</p>
<p>Abuse and addiction are separate and distinct from physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> and tolerance. Physicians should be aware that addiction may not be accompanied by concurrent tolerance and symptoms of physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> in all addicts. In addition, abuse of ULTRAM<span class="Sup">®</span> can occur in the absence of true addiction and is characterized by misuse for non-medical purposes, often in combination with other psychoactive substances.</p>
<p>Concerns about abuse and addiction should not prevent the proper management of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>.  However, all patients treated with opioids require careful monitoring for signs of abuse and addiction, because use of opioid analgesic products carries the risk of addiction even under appropriate medical use.</p>
<p>Proper assessment of the patient and periodic re-evaluation of therapy are appropriate measures that help to limit the potential abuse of this product.</p>
<p>ULTRAM<span class="Sup">®</span> is intended for oral use only.</p>
</div>
<div class="Section" data-sectionCode="34087-7">
<a name="section-10.3"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span></h2>
<p class="First">Tolerance is the need for increasing doses of drugs to maintain a defined effect such as <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> (in the absence of disease progression or other external factors). Physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> is manifested by withdrawal symptoms after abrupt discontinuation of a drug or upon administration of an antagonist (see also<span class="Bold"><a href="#withdrawal"> WARNINGS, Withdrawal</a></span>).</p>
<p>The opioid abstinence or withdrawal syndrome is characterized by some or all of the following: <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, <span class="product-label-link" type="condition" conceptid="435553" conceptname="Epiphora">lacrimation</span>, <span class="product-label-link" type="condition" conceptid="4170297" conceptname="Sniffles">rhinorrhea</span>, <span class="product-label-link" type="condition" conceptid="4089239" conceptname="Yawning">yawning</span>, perspiration, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, and <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">mydriasis</span>. Other symptoms also may develop, including <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">backache</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">joint pain</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal cramps</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, or <span class="product-label-link" type="condition" conceptid="141693" conceptname="Elevated blood-pressure reading without diagnosis of hypertension">increased blood pressure</span>, <span class="product-label-link" type="condition" conceptid="4313591" conceptname="Respiratory rate">respiratory rate</span>, or heart rate.</p>
<p><span class="Bold">Generally, tolerance and/or withdrawal are more likely to occur the longer a patient is on continuous therapy with ULTRAM<span class="Sup">®</span>.</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-11"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">Acute overdosage with tramadol can be manifested by <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> progressing to <span class="product-label-link" type="condition" conceptid="4229897" conceptname="Stupor">stupor</span> or <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, skeletal muscle <span class="product-label-link" type="condition" conceptid="4002033" conceptname="Muscle relaxation">flaccidity</span>, <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> and <span class="product-label-link" type="condition" conceptid="4308436" conceptname="Cold sweat">clammy</span> skin, <span class="product-label-link" type="condition" conceptid="435279" conceptname="Tonic pupillary reaction">constricted pupils</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Deaths</span> due to <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> have been reported with abuse and misuse of tramadol (see<span class="Bold"><a href="#misuseabuse"> WARNINGS, Misuse, Abuse, and Diversion</a></span>). Review of case reports has indicated that the risk of fatal <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> is further increased when tramadol is abused concurrently with alcohol or other CNS depressants, including other opioids.</p>
<p>In the treatment of tramadol overdosage, primary attention should be given to the re-establishment of a patent airway and institution of assisted or controlled ventilation. Supportive measures (including oxygen and vasopressors) should be employed in the management of circulatory <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span> and <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span> accompanying <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> as indicated. <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">Cardiac arrest</span> or <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span> may require cardiac massage or defibrillation.</p>
<p>While naloxone will reverse some, but not all, symptoms caused by overdosage with tramadol, the risk of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> is also increased with naloxone administration. In animals, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> following the administration of toxic doses of ULTRAM<span class="Sup">®</span> could be suppressed with barbiturates or benzodiazepines but were increased with naloxone. Naloxone administration did not change the lethality of an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> in mice. Hemodialysis is not expected to be helpful in an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> because it removes less than 7% of the administered dose in a 4-hour dialysis period.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-12"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.1"></a><p></p>
<h2>Adults (17 years of age and over)</h2>
<p class="First">For patients with moderate to moderately severe <span class="product-label-link" type="condition" conceptid="436096" conceptname="Chronic pain">chronic pain</span> not requiring rapid onset of <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesic effect</span>, the tolerability of ULTRAM<span class="Sup">®</span> can be improved by initiating therapy with the following titration regimen: ULTRAM<span class="Sup">®</span> should be started at 25 mg/day qAM and titrated in 25 mg increments as separate doses every 3 days to reach 100 mg/day (25 mg q.i.d.). Thereafter the total daily dose may be increased by 50 mg as tolerated every 3 days to reach 200 mg/day (50 mg q.i.d.). After titration, ULTRAM<span class="Sup">®</span> 50 to 100 mg can be administered as needed for <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> relief every 4 to 6 hours<span class="Bold"> not to exceed 400 mg/day.</span></p>
<p>For the subset of patients for whom rapid onset of <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesic effect</span> is required and for whom the benefits outweigh the risk of discontinuation due to adverse events associated with higher initial doses, ULTRAM<span class="Sup">®</span> 50 mg to 100 mg can be administered as needed for <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> relief every four to six hours,<span class="Bold"> not to exceed 400 mg per day.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.2"></a><p></p>
<h2>Individualization of Dose</h2>
<p class="First">Good <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> management practice dictates that the dose be individualized according to patient need using the lowest beneficial dose. Studies with tramadol in adults have shown that starting at the lowest possible dose and titrating upward will result in fewer discontinuations and increased tolerability.</p>
<ul class="Disc">
<li>In all patients<span class="Bold"> with creatinine clearance less than 30 mL/min, </span>it is recommended that the dosing interval of ULTRAM<span class="Sup">®</span> be increased to 12 hours, with a maximum daily dose of 200 mg. Since only 7% of an administered dose is removed by hemodialysis,<span class="Bold"> dialysis patients </span>can receive their regular dose on the day of dialysis.</li>
<li>The recommended dose for adult patients with<span class="Bold"> cirrhosis </span>is 50 mg every 12 hours.</li>
<li>In general, dose selection for an elderly patient over 65 years old should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal or cardiac function and of concomitant disease or other drug therapy. For elderly patients<span class="Bold"> over 75 years old, </span>total dose should not exceed 300 mg/day.</li>
</ul>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-13"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">ULTRAM<span class="Sup">®</span> (tramadol hydrochloride) Tablets - 50 mg are white, capsule-shaped, coated tablet imprinted "ULTRAM" on one side and "06 59" on the scored side.</p>
<p>Bottles of 100 tablets: NDC 50458-659-60</p>
<div class="Section" data-sectionCode="44425-7">
<a name="section-13.1"></a><p></p>
<p class="First">Dispense in a tight container. Store at 25°C (77°F); excursions permitted to 15  –30°C (59 – 86°F).</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-14"></a><p></p>
<p class="First">Product of Switzerland</p>
<p>Manufactured by:</p>
<p>Janssen Ortho, LLC<br>Gurabo, Puerto, Rico 00778</p>
<p>Manufactured for:</p>
<p>Janssen Pharmaceuticals, Inc.<br>Titusville, New Jersey 08560</p>
<p>© Janssen Pharmaceuticals, Inc. 2003<br>Revised July 2014</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-15"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL</h1>
<p class="First"><span class="Bold">NDC 54569-4089-0</span></p>
<p>Packaged by:<br><span class="Bold">A-S Medication Solutions</span><br>Libertyville, IL 60048</p>
<br><div class="Figure"><img alt="4089-0.jpg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=288ddb7b-29e4-46c7-9d84-38a188231710&amp;name=4089-0.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ULTRAM 		
					</strong><br><span class="contentTableReg">tramadol hydrochloride tablet, coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54569-4089(NDC:50458-659)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">CIV    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>tramadol hydrochloride</strong> (tramadol) </td>
<td class="formItem">tramadol hydrochloride</td>
<td class="formItem">50 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>starch, corn</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>modified corn starch (1-octenyl succinic anhydride)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>hypromelloses</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>lactose</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>cellulose, microcrystalline</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>polyethylene glycols</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>polysorbate 80</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium starch glycolate type a potato</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>titanium dioxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>carnauba wax</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE</td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (capsule-shaped) </td>
<td class="formLabel">Size</td>
<td class="formItem">13mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">ULTRAM;06;59</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54569-4089-0</td>
<td class="formItem">20  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:54569-4089-1</td>
<td class="formItem">30  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:54569-4089-5</td>
<td class="formItem">15  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020281</td>
<td class="formItem">03/03/1995</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>A-S Medication Solutions LLC
							(830016429)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">A-S Medication Solutions LLC</td>
<td class="formItem"></td>
<td class="formItem">830016429</td>
<td class="formItem">repack(54569-4089)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 10/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>a04950a6-a80c-4875-9098-1bfcf1ab0939</div>
<div>Set id: 288ddb7b-29e4-46c7-9d84-38a188231710</div>
<div>Version: 1</div>
<div>Effective Time: 20141012</div>
</div>
</div> <div class="DistributorName">A-S Medication Solutions LLC</div></p>
</body></html>
